At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 23 enrolled
Drug / intervention
saracatinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of the c-SRC Inhibitor AZD0530 After Four Cycles of Cytoreductive Chemotherapy for Patients With Extensive Stage Small Cell Lung Carcinoma
In Brief
A Phase 2 clinical trial evaluating saracatinib for Extensive Stage Small Cell Lung Cancer and 3 related conditions. Completed, enrolled 23 participants across 1 site.
Detailed Summary
AZD0530 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II study is studying how well giving AZD0530 works in treating patients with extensive-stage small cell lung cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsExtensive Stage Small Cell Lung Cancer, Lung Metastases, Malignant Pleural Effusion, Recurrent Small Cell Lung Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 2007
Enrollment StartNov 2007
Primary CompletionNov 2008
Study CompletionMay 2013
TodayJul 2026
First PostedSep 12, 2007
Enrollment StartNov 1, 2007
Primary CompletionNov 1, 2008
Study CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 18.8 years ago
Interventions
saracatinibdrug
Given orally